Verogen's ForenSeq kit and Thermo Fisher Scientific's Precision ID Whole Genome Panel can now be used to create DNA profiles for a national repository.
The LeukoStrat CDx FLT3 Mutation Assay can now be used in Japan as the CDx for quizartinib for the treatment of FLT3-ITD positive relapsed or refractory AML.
The UK Competition and Markets Authority has announced concerns that the $1.2 billion merger will reduce competition for Illumina and could scrutinize it further.
In a point-counterpoint in the Boston Globe, researchers discuss the potential of gene editing to prevent Lyme disease, but also the pitfalls of doing so.
